The experience of using agomelatine (Valdoxan) in the treatment of generalised anxiety disorder; Опыт применения агомелатина (Вальдоксана) при лечении генерализованного тревожного расстройства

Generalised anxiety disorder (GAD) is one of the most common anxiety disorders worldwide. Without treatment, GAD is characterised by a chronic course and significantly impairs social and occupational functioning. The main method of treating GAD in clinical practice is psychopharmacotherapy. Despite the fact that psychiatrists have a fairly large number of psychotropic drugs at their disposal, which are used in accordance with international and domestic clinical guidelines for the treatment of GAD, a number of therapeutic aspects remained unresolved until recently. In the updated clinical guidelines, agomelatine, an antidepressant that acts on melatonergic (MT1, MT2) and serotonergic (5-HT2C) receptors, was included among the first-line drugs for the treatment of GAD. The efficacy of agomelatine in treating GAD symptoms has been demonstrated in a number of randomised clinical trials. This article presents our own observations, illustrating some aspects of the use of agomelatine in real clinical practice. © 2025 Elsevier B.V., All rights reserved.